美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Deals:
      




      Omnicom announced it will acquire Interpublic Group (IPG), marking one of the biggest mergers in the history of the advertising industry if it goes through.
      




      The European Commission greenlit Novo Holdings’ $16.5 billion acquisition of Catalent.
      




      Kester Capital acquired EMAS Pharma.
      




      Ro said it will provide access to single-dose vials of Eli Lilly’s weight-loss drug Zepbound to patients with obesity.
      




      Haleon announced that it is the official consumer healthcare product partner of U.S. Soccer. 
      




      Hepion Pharmaceuticals terminated its merger agreement with Pharma Two B.
      




      Penn Medicine partnered with Mark Cuban Cost Plus Drug Company.
      




      Walgreens reportedly entered into talks to sell itself to private equity firm Sycamore Partners.
      




      Relation Therapeutics is teaming with GSK on two multi-program strategic collaborations. 
      




      AmMax Bio and MD Anderson unveiled agreements to advance development of AMB-066.
      




      FDA:
      




      The FDA granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older.
      




      The FDA submitted a proposed rule that could significantly lower the amount of nicotine in tobacco products and potentially prompt more people to quit smoking.
      




      Immuneering was granted FDA Fast Track Designation for IMM-1-104 in advanced melanoma.
      




      Olema Oncology announced FDA clearance of its Investigational New Drug Application for OP-3136.
      




      The FDA accepted GSK’s request to review data from the MATINEE study to grant a new indication for the use of Nucala (mepolizumab) in treating COPD.
      




      The agency granted Breakthrough Therapy Designation to Seres Therapeutics for SER-155.
      




      The FDA granted Breakthrough Therapy Designation to AstraZeneca’s Datopotamab deruxtecan (Dato-DXd).
      




      The FDA said it will continue to monitor the safety of Intercept Pharmaceuticals and Alfasigma’s rare liver disease drug Ocaliva after seeing evidence of “serious liver injury.”
      




      Layoffs:
      




      Editas Medicine announced a strategic pivot, laying off 65% of its workforce.
      




      BenevolentAI has plans for more layoffs as it intends to delist.
      




      Funding rounds: 
      




      VC firm Dimension raised a $500 million second fund.
      




      Rocket Pharmaceuticals announced a proposed public offering of $165 million in common stock.
      




      Danish biotech Citryll closed an oversubscribed €85 million Series B fundraise.
      




      Candel Therapeutics announced a $80 million proposed public offering.
      




      Veradermics raised $75 million in a Series B financing round.
      




      Tasca Therapeutics announced a $52 million Series A funding round.
      




      Pleno has raised an additional $25 million in private funding.
      




      Universe Pharmaceuticals announced a $15 million registered direct offering.
      




      Palisade Bio announced the pricing of a $5 million underwritten public offering.
      




      Sonnet BioTherapeutics announced a $3.9 million registered direct offering.
      




      CG Oncology announced its proposed public offering.
      




      Industry news:
      




      Lilly’s oral estrogen receptor degrader reduced death by 38% in a Phase 3 Trial.
      




      Additionally, Lilly CEO David Ricks said the drugmaker will start testing its GLP-1 medications as treatments for alcohol and drug addictions next year.
      




      New Amsterdam Pharma said that its CETP inhibitor succeeded in its third Phase 3 trial.
      




      Merck said its Phase 3 KEYLYNK-001 trial met the primary endpoint of progression-free survival in patients with advanced epithelial ovarian cancer.
      




      BioAge Labs said it will stop a Phase 2 trial testing its anti-obesity drug months after its $198 million initial public offering.
      




      Pfizer said Ibrance showed efficacy in a group of breast cancer patients who do not currently have access to the medicine.
      




      Baxter International announced five new injectable pharmaceutical product launches in the U.S.
      




      Swiss contract drugmaker Lonza said it plans to restructure and exit its capsules and health ingredients business.
      




      Keros Therapeutics said it has voluntarily halted two of three dosing arms of its experimental drug in a Phase 2 trial due to safety concerns.
      




      Corcept Therapeutics said its ALS drug failed to improve function in a Phase 2 study.
      




      Healthcare advertising platform DeepIntent launched its Data HealthChecks initiative.
      




      More than 97.5% of Vivendi shareholders voted to separate Canal+, ad business Havas and publisher Louis Hachette Group.
      




      Truth Initiative unveiled Outsmart Nicotine, a multi-platform campaign supported by agency partner Mojo Supermarket.
      




      Sanofi said sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients. 
      




      GSK’s blood cancer treatment Blenrep, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial.
      




      CervoMed said its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
      




      Imunon reported enhanced survival outcomes for IMNN-001 in advanced ovarian cancer treatment.
      




      Johnson & Johnson said Carvykti significantly improved minimal residual disease.
      




      Gilead Sciences and Arcellx said its anito-cel has a differentiated safety profile from Carvykti.
      




      Gilead also said it will start testing a drug that could prevent HIV infection with a single yearly shot.
      




      ConTIPI Medical and Eversana announced the domestic commercial launch of ProVate to help women experiencing pelvic organ prolapse.
      




      Longer-term data for Novartis’ Kisqali showed durable reduction in distant recurrence in a broad population of patients with early breast cancer.
      




      Additionally, Novartis’ Fabhalta improved hemoglobin levels with a rare blood disorder.
      




      AbbVie announced positive data from a third late-stage trial of a treatment for Parkinson’s disease and said it’s on track to seek approval for the drug from the FDA in 2025.
      




      Cardiff Oncology stock was trading 52% higher after its cancer drug shows positive response rate in Phase 2 trial. 
      




      Heartbeat launched a patient activation division that united Langland U.S. and BBK Worldwide.
      




      The Institute for Clinical and Economic Review released a new report arguing that U.S. healthcare costs rose by more than $800 million due to a handful of “unsupported” drug price increases.
      




      Acelyrin shares dropped after the decision to halt its eye disease treatment after clinical trial failure.
      




      Bayer bought HiDoc Technologies.
      




      Duality Biologics and BioNTech announced their therapy performed well against metastatic solid tumors. 
      




      See last week’s edition of Rx Rundown.